SCHEMBL1434579

SCHEMBL1434579

CC(C)(N)CCOC(=O)CN

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.35
HTR2C P28335 1/20 0.34
LMNA P02545 2/20 0.31
HSD17B10 Q99714 1/20 0.31
ADRA2A P08913 1/20 0.31
ADRA1A P35348 1/20 0.31
MAPT P10636 1/20 0.30
BLM P54132 1/20 0.30
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30
HTR1A P08908 1/20 0.30
CHRM5 P08912 1/20 0.30
CHRM1 P11229 1/20 0.30
TSHR P16473 1/20 0.30
CHRNB2 P17787 1/20 0.30
CHRM3 P20309 1/20 0.30
CYP2C19 P33261 1/20 0.30
CHRNA7 P36544 1/20 0.30
CHRNA4 P43681 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16881654 0.84 HTR2C (0.35) HTR2CLMNAHSD17B10ADRA2AADRA1A
SCHEMBL19787823 0.81 HTR2C (0.33) HTR2CLMNAHSD17B10ADRA2AADRA1A
SCHEMBL19387343 0.79 HTR2C (0.36) HTR2CLMNAHSD17B10
SCHEMBL13299282 0.79 DGKA (0.44) GRM4HTR2CLMNAHSD17B10ADRA2A
SCHEMBL18823278 0.77 HTR2C (0.41) HTR2CLMNAHSD17B10ADRA2AADRA1A
SCHEMBL23408786 0.76 HTR2C (0.34) HTR2CLMNAHSD17B10
SCHEMBL21742551 0.76 GRM4 (0.37) GRM4LMNAHSD17B10
SCHEMBL3121478 0.75 GLRA1 (0.39) HTR2CLMNAHSD17B10ADRA2AADRA1A
SCHEMBL28817815 0.75 HTR2C (0.43) HTR2CHTR1ACYP2C19
SCHEMBL18274698 0.75 MEN1 (0.52) HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099423-B1 METHOD OF HAIR TREATMENT UNILEVER PLC (GB) 2011-03-30 EP disclosed
US-20100291017-A1 Hair Treatment Compositions CONOPCO, INC. D/B/A UNILEVER 2010-11-18 US disclosed
EP-2097468-B1 COMPOSITION COMPRISING BRUSH COPOLYMER FOR TREATING HAIR UNILEVER PLC (GB) 2010-08-25 EP disclosed
EP-1959918-B1 HAIR TREATMENT COMPOSITIONS UNILEVER PLC (GB) 2010-06-30 EP disclosed
EP-1737420-B1 HAIR TREATMENT COMPOSITIONS UNILEVER PLC (GB) 2010-06-02 EP disclosed
US-20080286220-A1 Hair Treatment Compositions Comprising A Disaccharide, A Di-Acid And A Source Of Ammonium Ions CONOPCO, INC. D/B/A UNILEVER 2008-11-20 US disclosed
EP-1732506-B1 HAIR TREATMENT COMPOSITIONS COMPRISING A DISACCHARIDE, A DI-ACID AND A SOURCE OF AMMONIUM IONS UNILEVER PLC (GB) 2008-09-10 EP disclosed
US-20080193401-A1 Hair Treatment Composition CONOPCO, INC. D/B/A UNILEVER 2008-08-14 US disclosed
EP-1569602-B1 HAIR TREATMENT COMPOSITIONS UNILEVER PLC (GB) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100291017-A1 Hair Treatment Compositions OAT, NACA, BCAT2 GRM4 1232/4885HTR2C 487/4885LMNA 4071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.